Research

New hope and hard lessons: Parkinson’s research from iLCT and
Grand Challenges 2026

October 31 2026

Every September, scientists working on Parkinson’s disease gather at the Van Andel Institute in Grand Rapids, Michigan, for Grand Challenges in Parkinson’s Disease, a meeting where they share their latest findings. This year’s meeting followed on directly from the annual iLCT (international linked clinical trials) meeting, at which a committee of international experts do a deep dive into and prioritize candidate disease-modifying therapies for Parkinson’s, also hosted by the Van Andel Institute over the two days prior to Grand Challenges. The two back-to-back meetings, attended by our CEO Daniel, delivered a sharper picture of how the disease takes hold, often years before anyone notices a symptom, offering a cautious note of hope for one experimental treatment, and a clear “no” for a popular supplement.

An update on global clinical trials

We have previously mentioned the world’s largest ever clinical trial for Parkinson’s disease, the phase 3 EJS-ACT-PD trial centred in the UK, which is now one year in. This is what is known as a multi-arm multi-stage (MAMS) trial, with three drugs to be tested against a shared placebo group with 400 patients to be enrolled into each of the four arms. The study investigators have had steady enrolment to date, with patients being allocated into either the placebo arm or one of the first two drug arms (telmisartan, a blood pressure medication, and terazosin, also used for blood pressure as well as enlarged prostate). The third drug arm (ursodeoxycholic acid or UDCA, used for liver conditions) is due to commence enrolment from now. All of these drugs are repurposed drugs being considered for use in Parkinson’s to stop progression. We look forward to further updates on this exciting trial and of course the interim efficacy assessments as data are collected.

It is also exciting to see the Sleipnir phase 2a platform trial getting underway in Norway, with first patient first visit expected before Christmas. The idea behind this platform trial is to do a quick assessment of whether candidate drugs are getting where they need to (in the brain) and doing what we expect them to (known as target engagement). It is not always easy (or even possible) to determine whether a drug is doing what we think it should be, but through clever use of biomarkers and imaging, this approach will enable those that aren’t doing what we think they are to be fast-failed out of the trial, while those showing promise can be pushed through to the next stage. This not only accelerates progress, but also saves millions of dollars of vital funding from potentially being wasted on a dead end. Again, we eagerly anticipate seeing the progress on this important platform trial, which is an approach we would dearly love to emulate here in New Zealand, and for which we are presently seeking local funding partners/philanthropists.

A popular supplement falls short

In other news from Norway, but sadly not the news we hoped for, the results of NOPARK, a large phase 3 Norwegian trial, were recently published in the Journal of the American Medical Association. This trial tested nicotinamide riboside (NR), a form of vitamin B3 sold as an “NAD booster”. The idea was that it would help the cell’s energy factories, the mitochondria, which are impacted in Parkinson’s disease. Earlier small studies, including a promising phase 2 trial, had raised hopes.

NOPARK, led from Haukeland University Hospital in Bergen, gave 410 people diagnosed in the previous two years either 500 mg NR twice daily or a placebo pill for one year. The supplement clearly raised NAD levels in the body, but it did not slow the disease. On a standard rating scale covering movement, daily living and mood, the people taking NR worsened by about two-and-a-half points while the placebo group held steady. Non-movement symptoms also worsened slightly. These differences are small, below what doctors consider noticeable in everyday life, and serious side effects were not more common on the supplement. However, the result was quite unexpected, and in the opposite direction to what had been hoped for.

Study director Professor Charalampos Tzoulis said the results “do not support NR as a treatment to slow Parkinson’s disease”. The team advises against taking NAD-boosting supplements for Parkinson’s outside a clinical trial. The trial is also a reminder that a sound biological idea, and a drug that reaches its target, is not proof of benefit. Only a properly controlled study can show that.

An antibody that may slow the disease

Moving to the Grand Challenges talks, one of the most fascinating came from Professor Patrik Brundin of Roche, providing an update on their development of the monoclonal antibody prasinezumab. This laboratory-made antibody is designed to mop up alpha-synuclein, the protein that clumps together inside nerve cells in Parkinson’s. However, it was always a bit of a mystery why, after two high-profile trial failures at phase 2, Roche decided to push on and fund a phase 3 trial of prasinezumab likely costing tens of millions of dollars. That may now be explained.

Their first large-scale trial, PASADENA, missed its main goal after one year. However, many participants kept taking the drug, and their progress has now been followed for five years. Researchers compared them with a similar group of untreated people from a long-running international study. People on prasinezumab showed noticeably less worsening of movement symptoms, both when their usual medication had worn off and when it was working. Computer modelling suggests the drug bought roughly two extra years over five years of treatment.

A second trial, PADOVA, also missed its main goal. In a later analysis, though, one group stood out: people already taking levodopa. For them, the antibody slowed worsening by about 40–55% over two to two-and-a-half years. Brain scans hinted that the drug protected the cells most affected in Parkinson’s, but those results were not statistically confirmed. It is likely that any improvement in patients who were not taking levodopa at the start of the trial, but who commenced levodopa treatment during the trial, was masked by addition of symptomatic therapy (which of course it would have been unethical to deny; one of the many challenges associated with clinical trial design!).

Comparisons with an outside group are much less reliable than a proper placebo-controlled trial, as Professor Brundin acknowledged. But these promising findings were clearly enough to encourage Roche to invest in a new phase 3 trial, PARAISO, which aims to enrol about 900 people with early Parkinson’s who take levodopa. The new trial will test whether the antibody delays the point at which symptoms clearly worsen.

A slow process

Much of the Grand Challenges meeting focused on alpha-synuclein. Normally this protein helps nerve cells talk to each other. In Parkinson’s disease, it misfolds and sticks together, first in small clusters called oligomers and eventually in large clumps called Lewy bodies.

Professor Glenda Halliday of the University of Sydney, who received the meeting’s Jay Van Andel Award, explained that a mature Lewy body takes around ten years to form. That may help to explain why Parkinson’s is usually diagnosed long after it starts. The brain is very good at compensating, rewiring circuits and calling on support cells, so symptoms appear only once a large share of dopamine-producing cells has been lost, which is the end-stage of a long, slow process.

Professor Poul Henning Jensen of Aarhus University in Denmark described a new way to “see” the small oligomers, which are invisible to ordinary stains used to label brain tissue, but which may in fact be the most harmful form. In brains from people with dementia with Lewy bodies, the total amount of alpha-synuclein was normal, but more of it had formed larger clusters. His group also showed in cell experiments that correcting calcium handling inside cells helped them clear these clusters.

Another theme was where the disease begins. Professor Thomas Beach of Banner Health in Arizona, who has studied more than 2,500 donated brains, described two main routes of disease spread from the olfactory bulb (smell centre) to the cerebral cortex (higher cognitive functions and sensory perception): via the brainstem (which includes the midbrain where the dopamine-producing neurons of the substantia nigra reside), or via the amygdala (the emotional centre of the brain). This may help to explain why there is such a wide variety of symptoms and presentations of the disease. Other speakers, including Professor Valina Dawson of Johns Hopkins University, discussed “body-first” Parkinson’s, which may start in the gut (versus “brain-first” Parkinson’s), while Professor Kelvin Luk of the University of Pennsylvania showed using animal studies that the starting point shapes how the disease spreads.

Better ways to see the disease

A recurring frustration in Parkinson’s research is that there is no simple test to confirm the diagnosis or show whether a treatment is working. That is starting to change.

Professor Gabor Kovacs and colleagues at the University of Toronto showed that a small skin biopsy can do much of this work. Misfolded alpha-synuclein in skin can “seed” further clumping in a test tube, and the nature of that seeding distinguishes Parkinson’s disease from a related condition, multiple system atrophy (MSA). A parallel test for misfolded tau protein distinguishes progressive supranuclear palsy (PSP), which is often mistaken for Parkinson’s. Additionally, a blood marker of nerve damage helps separate MSA from Parkinson’s. Together, these tests could help ensure the right people join the right trials.

The meeting also had a sneak peak of some early results, presented by Dr Elpida Tsika, for a new brain-scan tracer developed by the Swiss company AC Immune together with Sweden’s Karolinska Institutet. This tracer is designed to light up alpha-synuclein clumps in a living person. Earlier tracers worked in MSA, where the clumps are large, but struggled to provide a signal in people with Parkinson’s. In a small number of volunteers, the new tracer detected signal in the expected areas, including a brightly lit up olfactory bulb, providing a beautiful validation of our very own Professor Curtis’s working hypothesis! If the new tracer holds up, it will allow clinical researchers to directly monitor disease progression and assess the effects of treatments designed to stop this progression.

What it all means

The overall picture is of a disease that starts silently, many years before diagnosis, and may begin in different places in different people. That understanding argues for earlier diagnosis and treatment, including tests that can tell which “form” of the disease an individual has. The tools to do both are being worked on diligently, including by our team here in NZ. It is only a matter of time!

The year’s results also show why well-designed trials matter. We now know that a highly plausible supplement with strong early evidence for an effect in Parkinson’s turned out not to help. Despite not being the big success the field had hoped for, it is important knowledge that teaches us more about the disease and closes one door among many. Another treatment has shown a sustained albeit modest signal over five years and is now going into a decisive phase 3 trial. Cure Parkinson’s NZ will keep reporting on these trials as results are announced, and we hope to bring clinical trial opportunities to Kiwis living with the disease within 2027.

Related blogs

Keeping abreast of global progress

CEO Daniel attends international meetings with partner organisations.

Read More
A call to action from The Lancet and a new direction

Prestigious British medical journals provide a state of play on Parkinson’s research and ask “what next”?

Read More
First demonstration that immunosuppression may help to slow Parkinson’s progression

A recently completed clinical trial reveals promise for the strategy of immunosuppression for slowing Parkinson’s progression

Read More
World-first 3D Model Explained

Animation that describes the world-first 3D visualization of the human olfactory system.

Read More